Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings Inc is a biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the healthcare diagnostics sector.

Reviva Pharmaceuticals is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a classification confidence of 0.92.

Reviva Pharmaceuticals has a negative net equity of -$1,345,820, indicating that its liabilities exceed its assets, and a current ratio of 0.93, suggesting limited short-term liquidity. The company's free cash flow is -$7,433,610, and its operating cash flow is -$11,725,810, both of which are negative and indicate significant cash outflows from operations.

The company's return on equity is 5.52%, which is positive but must be interpreted cautiously given the negative equity. Its return on assets is -0.55%, indicating that the company is not generating a return on its asset base. The debt-to-equity ratio is -0.25, which is unusual and suggests that the company has negative equity, further highlighting the financial challenges it faces.

Reviva Pharmaceuticals' revenue is not disclosed in the provided data, but the company's financial snapshot indicates a negative operating income of -$7,922,110 and a net income of -$7,433,610. The company's financial performance is below the industry median for profitability metrics, and its negative cash flows suggest operational inefficiencies or high costs.

The company's geographic exposure and segmental breakdown are not provided in the available data. However, the company's focus on healthcare diagnostics suggests that it may be exposed to regulatory and reimbursement risks in the healthcare sector. The lack of segmental data limits the ability to assess the company's diversification and risk profile.

The company's outlook for the current fiscal year is not provided in the available data. However, the negative operating and net income, along with the negative cash flows, suggest that the company is not currently generating positive returns. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's financial position remains challenging.

Recent events and filings for Reviva Pharmaceuticals are not detailed in the provided data. However, the company's financial snapshot and risk assessment suggest that it may be facing liquidity and operational challenges. The company's negative equity and cash flows indicate a need for strategic and financial restructuring.

- Reviva Pharmaceuticals has a negative net equity and a current ratio below 1, indicating significant liquidity challenges. - The company's return on equity is positive but must be interpreted with caution due to the negative equity. - The company's operating and net income are negative, suggesting operational inefficiencies or high costs. - The company's financial position is challenging, with negative cash flows and a debt-to-equity ratio that is unusual due to negative equity. - The company's geographic and segmental exposure is not disclosed, limiting the ability to assess diversification and risk. - The company's outlook for the current fiscal year is not provided, but the financial data suggests a need for strategic and financial restructuring.

Reviva Pharmaceuticals Holdings Inc (RVPH.O) has recorded its first analysis, establishing a baseline for future monitoring with no prior data available for delta computation. This initial snapshot reveals a shareholder base comprising seven top holders, though the company currently lacks analyst coverage, index membership, and reported officer counts in the available data. The most material development in this initial review is the addition of five new notable holders as of March 31, 2026. These investors entered the registry with positions ranging from 150 shares to 19,160 shares. The largest of these new positions, held by investor ID 467, represents a value of approximately $14,000 USD, while the other four additions hold stakes valued between $109 and $7,639 USD. Despite these new entries, the individual weight of each holder remains negligible, with the largest stake accounting for less than 0.000001% of the total equity. The collective value of these five new positions is minimal, suggesting that while institutional or specific investor interest is emerging, it has not yet translated into significant capital concentration or market-moving volume. This baseline data is critical for tracking future shifts in ownership structure for Reviva Pharmaceuticals. With no analyst estimates or financial history currently integrated into this specific view, the emergence of these seven top holders serves as the primary indicator of early market participation. Future updates will rely on this initial dataset to measure the growth or contraction of investor interest relative to these starting positions.

Operating income +43,4% YoY; Net income +46,2% YoY.

• ▍Operating income +43,4% YoY
• ▍Net income +46,2% YoY

Operating income +52,4% YoY; Net income +52,1% YoY.

• ▍Operating income +52,4% YoY
• ▍Net income +52,1% YoY

Operating income +25,3% YoY; Net income +23,0% YoY.

• ▍Operating income +25,3% YoY
• ▍Net income +23,0% YoY

Operating income +17,5% YoY; Net income +13,5% YoY.

• ▍Operating income +17,5% YoY
• ▍Net income +13,5% YoY

Operating income -$6.3M.

• ▍Operating income -$6.3M

Operating income -$8.5M.

• ▍Operating income -$8.5M

Operating income -$8.1M.

• ▍Operating income -$8.1M

Operating income -$7.9M.

• ▍Operating income -$7.9M

Operating income +34,4% YoY; Net income +33,6% YoY.

• ▍Operating income +34,4% YoY
• ▍Net income +33,6% YoY

Operating income +22,0% YoY; Net income +23,8% YoY.

• ▍Operating income +22,0% YoY
• ▍Net income +23,8% YoY
• ▍Free cash flow +23,8% YoY

Operating income −39,9% YoY; Net income −38,9% YoY.

• ▍Operating income −39,9% YoY
• ▍Net income −38,9% YoY
• ▍Free cash flow −38,9% YoY

Operating income −179,4% YoY; Net income −231,6% YoY.

• ▍Operating income −179,4% YoY
• ▍Net income −231,6% YoY
• ▍Free cash flow −231,6% YoY